The global prevalence of primary biliary cholangitis (PBC) has increased, particularly in the Western Pacific region of the world, according to study results published in Clinical Gastroenterology and ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

Lisa Woodcock's initial instinct when she first developed severe itching all over her body was to blame an allergic reaction ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Biliary atresia (BA) ... Chapman RW 1991 Role of immune factors in the pathogenesis of primary sclerosing cholangitis. Semin Liver Dis 11: 1–4. Article CAS PubMed Google Scholar ...

What is in a name; and why does the nomenclature of one disease, primary biliary cirrhosis, cause such contention that a proposed name change by those deeply committed to the advancement of its ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary ...